key: cord-326143-6ndqgxy8
authors: Wang, Qiang; Hu, Zhao
title: Successful recovery of severe COVID-19 with cytokine storm treating with extracorporeal blood purification
date: 2020-05-26
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.05.065
sha: 
doc_id: 326143
cord_uid: 6ndqgxy8

COVID-19 associated cytokine storm could induce ARDS rapidly and the patients would require the support of mechanic ventilation. However, the prognosis was not that optimistic. The outcome might be changed if the intervention of EBP was performed timely. We present a case of severe SARS-CoV-2 infection who recovered from cytokine storm.

The coronavirus disease 2019 (COVID-19) broke out throughout the world now. The total number of deaths has been Over 88900 up to now. The patients with confirmed COVID-19 progressed to acute respiratory distress syndrome (ARDS) rapidly in an incident rate as high as 41.8% 1 , and many of them require mechanic ventilation. In a cohort of an intensive care unit (ICU) from Italy, 1287 cases need respiratory support, and among them, 88% of patients (1150 cases) had to be supported with mechanical ventilation 2 . Apart from the desperate lacking of ventilator all over the world, mechanical ventilation could also cause barotrauma and ventilator-associated lung injury.

Cytokine storm has been disclosed as the main pathological characteristic of COVID-19 3 , and it is also the direct pathogenic contributor to induce ARDS. Cytokines could be eliminated effectively by extracorporeal blood purification (EBP) 4 , which thus could interrupt the initiation and progression of inflammation cascade in the scenario of COVID-19.

Accordingly, there may be a chance of avoiding incubation and mechanical ventilation. Herein, we report a case of severe SARS-CoV-2 infection with cytokine storm, who was completely recovered from cytokine storm using extracorporeal blood purification.

A 62-year-old male presented to the hospital with 8-day history of fever and 6-day history of cough and chest distress. The patient had a history of gallstone. He got fever on day 1 (February 14, 2020) and had chill, headache, muscle soreness, fatigue, nausea, cough, and chest distress and shortness of breath on day 3. Then, he was quarantined in a hotel. Being tested positive J o u r n a l P r e -p r o o f for SARS-CoV-2 on day 5, he received oseltamivir, moxifloxacin and Lianhua Qingwen capsule (Chinese medicine) in the outpatient.

He was admitted to the hospital with fever, cough and mild chest distress on day 9. Arbidol, hydroxychloroquine, oseltamivir, and Lianhua Qingwen capsule were administered. Supplemental oxygen was delivered by nasal cannula at 2 L/min. Alterations in hepatic function were showed: levels of alanine aminotransferase (81 U/L, normal range: 9-50 U/L) and aspartate aminotransferase (94 U/L, normal range: 15-40 U/L) were elevated, and CD3 and CD4 cell counts were markedly decreased (Supplemental Table) on day 10. Chest CT indicated multiple ground-glass opacities in bilateral lungs on day 11 (Supplemental Figure 1 . A-C). The peak of temperature was 38.5°C up to date. His vital signs remained clinically stable except oxygen saturation was 97% while providing oxygen at 3 L/min. IL-6 (198.66 pg/ml) was almost 10 folds of normal range (≤5.9 pg/ml) which indicated an initiation of cytokine storm on day 12 ( Figure 1 ). The EBP, including double plasma molecular adsorption system (BS330 and HA330II, Jafron, China) and plasma exchange (2000 ml each), was thus applied to remove the cytokines on day 13. The BS330 and HA330II were installed in series after the plasma separator (EC-4W, Asahi) with a blood flow velocity of 80-100 ml/min and a separating speed of 20-25ml/min, and the duration of the treatments was 6 hours. The plasma exchange was then conducted. Intravenous methylprednisolone (40 mg daily) was used to suppress the inflammation reaction. The patient was largely stable until the chest distress exacerbated and blood in phlegm developed on day 14. He then progressed to type I respiratory failure (partial pressure of oxygen 51 mmHg, partial pressure of carbon dioxide 32 mmHg) with 89% oxygen saturation while the oxygen flow was 3 L/min. High-flow oxygen (40 L/min) was initiated to keep the oxygen saturation values between 96-99%. Hydroxychloroquine was discontinued due to a long QT interval. The EBP therapy continued on days 14 and 15 respectively.

The patient was transferred into ICU on day 15. Given the acute inflammatory reaction, methylprednisolone was improved to 60 mg twice daily, and piperacillin-tazobactam (4.5 g administered intravenously every 8 hours) was initiated concerning about the hospital-acquired pneumonia. Acetylcysteine was used to dilute the phlegm. The human serum albumin and other supportive care were also administered. The clinical condition of the patient was improved on day 16 and was stable J o u r n a l P r e -p r o o f thereafter, and his hepatic function was back to normal as well. The body temperature returned to normal on day 17. The IgM of anti-SARS-CoV-2 was identified (77.11 AU/mL, normal value <10 AU/mL) at the same day. Methylprednisolone was gradually reduced and discontinued on day 23. The lesions on chest CT was confined on day 17 and further alleviated on day 21 and almost disappeared on day 33 (Supplemental Figure 1) . Low flow rate of oxygen (2 L/min) was delivered instead of high-flow oxygen on day 26 then discontinued on day 36. He was asymptomatic at rest and had no shortness of breath while doing activity training. His renal function was unaffected and immunoglobulin levels including IgG, IgM, IgA and IgE were normal throughout the clinical course. Complement C3 level was staying below the normal range (0.9-1.8 g/L) during the hospital duration (Supplemental Table 1 ). C4 level (<0.06 g/L, normal range: 0.1-0.4 g/L) was reduced at day 16 and was back to normal (0.15 g/L) on day 31. The nucleic acid testing of SARS-CoV-2 was negative in four different times. He was discharged on day 38.

The management of COVID-19 in critical cases is still challenging nowadays. Respiratory and circulation supports, such as mechanic ventilation and extracorporeal membrane oxygenation (ECMO), were almost the last defense for severe COVID-19 5 . Although specific methods to intervene the progression of critical cases are unknown, the effects of EBP in treatment of COVID-19 associated cytokine storm have not been emphasized. The outcome of the present case of COVID-19 with ARDS is promising. Pulmonary fibrosis was not observed up to date.

EBP was suggested to interrupt the inflammation cascade and stop the progression of cytokine storm in this case. There were obvious peak levels of cytokines and bent over after the initiation of EBP on day 13. HA330 improved oxygenation and lung mechanics by removing circulating and alveolar cytokine levels 6 , and BS330 adsorbed bilirubin so as to attenuate liver injury 7 .The EBP that combined the double plasma molecular adsorption system and plasma exchange can directly reduce the cytokines. Although methylprednisolone was also administered synchronously, it has been identified that the significant time point of IL-6 reduce was the seventh day rather than the first three days in ARDS 8 

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Cytokine removal in human septic shock: Where are we and where are we going? Ann Intensive Care

Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure

Hemoadsorption therapy in the critically ill: solid base but clinical haze

Preparation and Adsorption Properties of Novel Porous Microspheres with Different Concentrations of Bilirubin

Effect of methylprednisolone on inflammatory markers and patients' outcomes in acute respiratory distress syndrome

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan


